Advanced Biomed Inc.
Business
Advanced Biomed Inc. is a holding company that develops microfluidic and semiconductor‑based liquid biopsy and 3D cell culture technologies for oncology detection and precision medicine. It offers automated instruments and consumables including A+Pre, AC‑1000, A+CellScan, A+SCDrop, microfluidic biochips, immunostaining kits, the A+PerfusC™ 3D culture system, and tumor screening/CTC capture services. The company operates through R&D, regulatory/registration, manufacturing and market operation divisions via Advanced Biomed Taiwan, Advanced Biomed HK, and a Shanghai subsidiary. It targets commercialization and distribution initially in China with plans for localized production, product registration and market expansion into North America and Europe.
Summary from filing dated 2025-10-08
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 |
|---|---|---|---|
| Research and development expenses | −909,771 | −880,193 | |
| General and administrative expenses | −2 | −2 | |
| Total operating expenses | −3 | −3 | |
| Interest income | 24,915 | 53,495 | |
| Other expense, net | −262,848 | −294,201 | |
| Total other expense, net | −237,933 | −240,706 | |
| Loss before tax expense | −3 | −3 | |
| Income tax expense | — | — | |
| Net Loss | −3 | −3 | |
| Foreign currency translation gain, net of taxes | 218,346 | 319,324 | |
| Total comprehensive loss | −3 | −2 | |
| Basic (in Dollars per share) | −0.16 | −0.14 | |
| Diluted (in Dollars per share) | −0.16 | −0.14 | |
| Basic (in Shares) | 21 | 20 | |
| Diluted (in Shares) | 21 | 20 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 |
|---|---|---|---|---|
| Cash | 3 | 3 | — | |
| Prepaid expenses and other current assets, net | 3 | 443,137 | — | |
| Total current assets | 6 | 3 | — | |
| Equipment, net | 331,346 | 524,528 | — | |
| Right-of-use assets, net | 65,399 | 126,740 | — | |
| Intangible assets, net | — | 118,998 | — | |
| Deferred initial public offering (IPO) costs | — | 638,871 | — | |
| Other non-current assets | 83,027 | — | — | |
| Total non-current assets | 479,772 | 1 | — | |
| TOTAL ASSETS | 7 | 4 | — | |
| Accounts payable, accruals, and other current liabilities (including amount due to related parties major stockholders as of June 30, 2025 and 2024, with $172,767 and $113,812 due to related parties related corporations, and $916,036 and $674,262 due to related corporations, respectively (1)) | 3 | 3 | — | |
| Lease payable - current | 35,811 | 62,211 | — | |
| Total current liabilities | 3 | 3 | — | |
| Lease payable non-current | 5,879 | 64,529 | — | |
| Total non-current liabilities | 145,651 | 64,529 | — | |
| TOTAL LIABILITIES | 3 | 3 | — | |
| Commitments and contingencies | — | — | — | |
| Common stock $0.001 par value per share; as of June 30, 2025 and 2024; 400,000,000 and 400,000,000 shares authorized; 21,640,000 and 20,000,000 shares issued and outstanding, respectively* | 21,640 | 20,000 | — | |
| Additional paid-in capital | 21 | 16 | — | |
| Accumulated deficits | −19 | −16 | — | |
| Accumulated other comprehensive income | 1 | 1 | — | |
| Total stockholders equity | 3 | 2 | 1 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 7 | 4 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 |
|---|---|---|---|
| Depreciation and amortization | 343,830 | 399,602 | |
| Prepaid expenses and other current assets | −3 | −279,425 | |
| Accounts payable, accruals and other current liabilities | −117,661 | 479,634 | |
| Lease obligations, net cash | −23,709 | — | |
| Other non-current assets | −83,027 | 56,127 | |
| Cash used in operating activities | −6 | −2 | |
| Purchase of equipment | −31,650 | −74,110 | |
| Cash used in investing activities | −31,650 | −74,110 | |
| Net proceeds from issuance of stock in IPO/(prepayments for IPO costs) | 5 | −85,400 | |
| Cash provided by financing activities | 6 | 2 | |
| Foreign currency effect | 218,346 | 319,324 | |
| Net change in cash | 295,942 | −14,306 | |
| Cash paid for interest | — | — | |
| Cash paid for taxes | — | — | |
| Cash received for interest | 24,915 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Advanced Biomed Inc.'s CIK number?
Advanced Biomed Inc.'s SEC CIK number is 0001941029 (1941029). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Advanced Biomed Inc.'s SEC filings?
All of Advanced Biomed Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.